Sort   by:  
 Page size 
UnknownFirst-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
Not available
S-EPMC7665848 | biostudies-literature
UnknownSubtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer.
Not available
S-EPMC7687888 | biostudies-literature
UnknownAST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer.
Not available
S-EPMC9501578 | biostudies-literature
UnknownHigh-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes.
Not available
S-EPMC9506379 | biostudies-literature
UnknownSubclassification, survival prediction and drug target analyses of chemotherapy-naive muscle-invasive bladder cancer with a molecular screening.
Not available
S-EPMC5995241 | biostudies-literature
UnknownDiagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
Not available
S-EPMC6428315 | biostudies-literature
UnknownIsolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer.
Not available
S-EPMC8944243 | biostudies-literature
UnknownFOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
Not available
S-EPMC7230662 | biostudies-literature
UnknownDrug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
Not available
S-EPMC7723234 | biostudies-literature
UnknownDefining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Not available
S-EPMC5940636 | biostudies-literature
Sort   by:  
 Page size